{
    "nctId": "NCT01276054",
    "briefTitle": "Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.",
    "officialTitle": "Reducing the Incidence and Severity of Arm Lymphedema With Axillary Reverse Mapping and Implementation of a Lymphedema Screening and Intervention Program",
    "overallStatus": "TERMINATED",
    "conditions": "Lymphedema, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 4,
    "primaryOutcomeMeasure": "Whether or Not a Patient Has Developed Grade 1+ LE",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Stage 0, I, and II Breast Cancer\n* Not pregnant or breastfeeding\n* Breast cancer or prophylactic mastectomy requiring axillary nodal staging\n* Ability to read and/or comprehend consent form and questionnaires\n* Ability to follow-up per protocol\n* Unilateral axillary staging\n\nExclusion Criteria:\n\n* Stage 3\n* Previous axillary lymph node dissection\n* Neoadjuvant chemotherapy or hormonal therapy exceeding greater than 30 days duration\n* Allergy to blue dyes or iodine; NOTE: a non-blue dye or non-iodine-containing dye may be used in these patients\n* Patients with implanted medical devices such as a pacemaker may undergo perometry, but not BIS (Bioelectrical Impedance Spectroscopy)\n* Previous diagnosis of LE (lymphedema) of either extremity\n* Bilateral axillary staging",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}